Number of the records: 1
5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes
- 1.
SYSNO ASEP 0367817 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes Author(s) Pardini, Barbara (UEM-P)
Kumar, R. (DE)
Naccarati, Alessio (UEM-P)
Prasad, R. B. (DE)
Försti, A. (DE)
Hemminki, K. (DE)
Vodička, Pavel (UEM-P) RID
Bermejo, J. L. (DE)Source Title British Journal of Clinical Pharmacology. - : Wiley - ISSN 0306-5251
Roč. 72, č. 1 (2011), s. 162-163Number of pages 2 s. Language eng - English Country GB - United Kingdom Keywords fluorouracil ; DNA-damage ; nepolymorphisms Subject RIV EB - Genetics ; Molecular Biology R&D Projects GAP304/10/1286 GA ČR - Czech Science Foundation (CSF) GP305/09/P194 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z50390512 - UEM-P (2005-2011) UT WOS 000292505500019 EID SCOPUS 79958749939 DOI 10.1111/j.1365-2125.2010.03892.x Annotation Treatment with 5-fluorouracil is known to improve survival in various cancers, mainly in colorectal cancer. Crucial metabolite of 5 FU depends on methylene-tetrahydro-folate reductase, MTHFR. We investigated 6 genetic variants in the MTHFR and MTRR genes on the clinical outcome of 273 patients treated by 5FU. One variant in MTHFR gene showed association with progression-free survival in heterozygotes and homozygotes bearers and is connected with statistically significant better survival. None of other investigated variants showed any association with the survival. Workplace Institute of Experimental Medicine Contact Lenka Koželská, lenka.kozelska@iem.cas.cz, Tel.: 241 062 218, 296 442 218 Year of Publishing 2012
Number of the records: 1